Spruce Biosciences Stock EBITDA
| SPRB Stock | USD 0.55 0.02 3.77% |
Spruce Biosciences fundamentals help investors to digest information that contributes to Spruce Biosciences' financial success or failures. It also enables traders to predict the movement of Spruce Stock. The fundamental analysis module provides a way to measure Spruce Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spruce Biosciences stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -47.4 M | -49.7 M |
Spruce | EBITDA |
Spruce Biosciences Company EBITDA Analysis
Spruce Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Spruce Biosciences EBITDA | (47.37 M) |
Most of Spruce Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spruce Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Spruce EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Spruce Biosciences is extremely important. It helps to project a fair market value of Spruce Stock properly, considering its historical fundamentals such as EBITDA. Since Spruce Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spruce Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spruce Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Spruce Ebitda
Ebitda |
|
According to the company disclosure, Spruce Biosciences reported earnings before interest,tax, depreciation and amortization of (47.37 Million). This is 105.4% lower than that of the Biotechnology sector and 147.29% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.21% higher than that of the company.
Spruce EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spruce Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spruce Biosciences could also be used in its relative valuation, which is a method of valuing Spruce Biosciences by comparing valuation metrics of similar companies.Spruce Biosciences is currently under evaluation in ebitda category among its peers.
Spruce Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Spruce Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Spruce Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Spruce Biosciences' value.| Shares | Citadel Advisors Llc | 2024-09-30 | 77.1 K | Lion Point Capital, Lp | 2024-09-30 | 75 K | Northern Trust Corp | 2024-09-30 | 74.9 K | State Street Corp | 2024-06-30 | 64.4 K | Two Sigma Advisers, Llc | 2024-06-30 | 45.7 K | Bridgeway Capital Management, Llc | 2024-09-30 | 40 K | Tower Research Capital Llc | 2024-06-30 | 33.1 K | Jane Street Group Llc | 2024-06-30 | 30.8 K | Two Sigma Investments Llc | 2024-09-30 | 23.4 K | Rivervest Venture Management Llc | 2024-09-30 | 2.9 M | The Carlyle Group Inc | 2024-09-30 | 2.9 M |
Spruce Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (15.63) % | ||||
| Current Valuation | (34.94 M) | ||||
| Shares Outstanding | 41.3 M | ||||
| Shares Owned By Insiders | 10.50 % | ||||
| Shares Owned By Institutions | 41.43 % | ||||
| Number Of Shares Shorted | 232.77 K | ||||
| Price To Book | 0.42 X | ||||
| Price To Sales | 3.08 X | ||||
| Revenue | 10.09 M | ||||
| EBITDA | (47.37 M) | ||||
| Net Income | (47.92 M) | ||||
| Cash And Equivalents | 93.3 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 4.61 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.55 X | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | (33.27 M) | ||||
| Short Ratio | 0.16 X | ||||
| Earnings Per Share | (0.95) X | ||||
| Target Price | 2.33 | ||||
| Number Of Employees | 29 | ||||
| Beta | 2.37 | ||||
| Market Capitalization | 21.88 M | ||||
| Total Asset | 103.95 M | ||||
| Retained Earnings | (197.23 M) | ||||
| Working Capital | 77.72 M | ||||
| Net Asset | 103.95 M |
About Spruce Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spruce Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spruce Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spruce Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:Check out Spruce Biosciences Piotroski F Score and Spruce Biosciences Altman Z Score analysis. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.